You're tuned in to Markets Desk, let's get you caught up on the stories moving the needle today.
Eli Lilly is generating serious buzz beyond its already blockbuster Zepbound franchise. The company's next-generation anti-obesity drug has posted highly encouraging clinical trial results, raising the prospect of an even larger revenue driver ahead. For a pharma giant already riding the GLP-one wave, that pipeline depth is a meaningful differentiator for long-term investors.
Shifting to semiconductors, AMD has crossed the one trillion dollar market capitalization threshold, a milestone that puts it in rare company — but the question the market is asking is whether it can close the gap on Nvidia. The honest answer, for now, is no. Nvidia is growing faster and commands a larger footprint across AI infrastructure, meaning AMD's trillion-dollar moment is impressive, but the crown isn't changing hands yet.
Meanwhile, the Social Security story deserves attention from anyone watching fiscal policy. The program's two thousand twenty seven cost-of-living adjustment is shaping up to be one of the largest in thirty-five years, driven in part by elevated inflation readings. While that sounds like good news for retirees, analysts warn the financial strain on the program itself could accelerate its long-term funding pressures.
That's the tape. Markets Desk, signing off the floor.
